Assembly Biosciences, Inc.
ASMBHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeAssembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Valued at $549.5M, ASMB is a small-cap name in its sector. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection.
Market Cap
$549.5M
Beta
—
P/E (TTM)
346.63
P/E (Fwd)
-10.23
EPS (TTM)
$0.08
EPS (Fwd)
$-2.71
ROE
-5.7%
ROA
-5.1%
Cash
$226.6M
Total Debt
$2.5M
Free CF
—
52W Change
96.0%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $226.6M in cash comfortably exceeding the $2.5M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Return on equity stands at -5.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The elevated P/E ratio means the stock is priced for significant future growth. If earnings disappoint, the price correction could be sharp. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Assembly Biosciences, Inc. and its sector.